Veristat was brought on to write a sponsor’s protocol for a novel treatment that injects engineered exosomes into solid tumors. The application of a set of nuanced response criteria required information collected from injected lesions and non-injected lesions to determine a tumor’s response to the treatment.
- Indication: Advanced metastatic recurrent injectable solid tumors
- What Kind of Trial: Immunotherapy with intratumoral delivery
- Primary Services Provided:
- Strategic consulting
- Protocol development
- Statistical analysis plan development
- Project management
Download the available case study to learn more.